Real-time education makes headlines

Share this article:

Do physicians need a CNN for CME? Some vendors think so and are implementing real-time educational offerings.

“The doctor will not accept in their consumer life what they accept in their professional life: that the forest fire happened two months ago and they hear about it now for the first time,” said Bob Stern, CEO of breaking medical news site MedPage Today. “That's an unacceptable experience.”

The “rapid-distribution” model of presenting news from meetings or journals with credit is becoming more important as a way to meet physician needs, agreed Mario Nacinovich, Jr., co-founder/co-CEO, Fission Communications. Indeed, “some CME stakeholders are reconsidering the lengthy content development and production processes associated with traditional enduring materials,” he said.

That's not to say the traditional model is dead—far from it. According to a recent Pri-Med study, readership of one of its print CME newsletters rose 85% from 2005 to 2006. The study shows physicians still value print as a way to obtain information on new treatment options and therapies, Pri-Med's director of physician insights, Anne Goodrich, said.

Others making the immediacy push include vendors such as Epocrates, which disseminates scientific findings in lessons on handheld devices.

But MedPage Today is seriously embracing the daily news model. Its redesigned homepage contains about 12-15 stories displayed in a newspaper-like format and more standalone video stories. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...